IOT Quote, Financials, Valuation and Earnings

AppLovin has a net margin of -3.24% compared to Samsara's net margin of 43.65%. Samsara's return on equity of -15.9% beat AppLovin's return on equity of 162.55%.

Samsara has a consensus price target of $48.90, signalling upside risk potential of 14.75%. On the other hand AppLovin has an analysts' consensus of $486.60 which suggests that it could grow by 40.52%. Given that AppLovin has higher upside potential than Samsara, analysts believe AppLovin is more attractive than Samsara.

Samsara has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison AppLovin has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Samsara has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AppLovin offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Samsara pays -- of its earnings as a dividend. AppLovin pays out -- of its earnings as a dividend.

Samsara quarterly revenues are $346.3M, which are smaller than AppLovin quarterly revenues of $1.4B. Samsara's net income of -$11.2M is lower than AppLovin's net income of $599.2M. Notably, Samsara's price-to-earnings ratio is -- while AppLovin's PE ratio is 76.28x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Samsara is 18.98x versus 25.58x for AppLovin. Usually stocks with elevated PS ratios are considered overvalued.

Enfusion has a net margin of -3.24% compared to Samsara's net margin of 0.23%. Samsara's return on equity of -15.9% beat Enfusion's return on equity of 3.17%.

Samsara has a consensus price target of $48.90, signalling upside risk potential of 14.75%. On the other hand Enfusion has an analysts' consensus of $10.93 which suggests that it could fall by -1.82%. Given that Samsara has higher upside potential than Enfusion, analysts believe Samsara is more attractive than Enfusion.

Samsara has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Enfusion has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Samsara has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Enfusion offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Samsara pays -- of its earnings as a dividend. Enfusion pays out -- of its earnings as a dividend.

Samsara quarterly revenues are $346.3M, which are larger than Enfusion quarterly revenues of $52.9M. Samsara's net income of -$11.2M is lower than Enfusion's net income of $121K. Notably, Samsara's price-to-earnings ratio is -- while Enfusion's PE ratio is 371.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Samsara is 18.98x versus 6.60x for Enfusion. Usually stocks with elevated PS ratios are considered overvalued.

Klaviyo has a net margin of -3.24% compared to Samsara's net margin of -9.98%. Samsara's return on equity of -15.9% beat Klaviyo's return on equity of -4.73%.

Samsara has a consensus price target of $48.90, signalling upside risk potential of 14.75%. On the other hand Klaviyo has an analysts' consensus of $51.38 which suggests that it could grow by 49.62%. Given that Klaviyo has higher upside potential than Samsara, analysts believe Klaviyo is more attractive than Samsara.

Samsara has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Klaviyo has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Samsara has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Klaviyo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Samsara pays -- of its earnings as a dividend. Klaviyo pays out -- of its earnings as a dividend.

Samsara quarterly revenues are $346.3M, which are larger than Klaviyo quarterly revenues of $270.2M. Samsara's net income of -$11.2M is higher than Klaviyo's net income of -$27M. Notably, Samsara's price-to-earnings ratio is -- while Klaviyo's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Samsara is 18.98x versus 9.76x for Klaviyo. Usually stocks with elevated PS ratios are considered overvalued.

Palantir Technologies has a net margin of -3.24% compared to Samsara's net margin of 9.55%. Samsara's return on equity of -15.9% beat Palantir Technologies's return on equity of 10.88%.

Samsara has a consensus price target of $48.90, signalling upside risk potential of 14.75%. On the other hand Palantir Technologies has an analysts' consensus of $86.61 which suggests that it could fall by -10.24%. Given that Samsara has higher upside potential than Palantir Technologies, analysts believe Samsara is more attractive than Palantir Technologies.

Samsara has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Palantir Technologies has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Samsara has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palantir Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Samsara pays -- of its earnings as a dividend. Palantir Technologies pays out -- of its earnings as a dividend.

Samsara quarterly revenues are $346.3M, which are smaller than Palantir Technologies quarterly revenues of $827.5M. Samsara's net income of -$11.2M is lower than Palantir Technologies's net income of $79M. Notably, Samsara's price-to-earnings ratio is -- while Palantir Technologies's PE ratio is 507.89x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Samsara is 18.98x versus 82.53x for Palantir Technologies. Usually stocks with elevated PS ratios are considered overvalued.